Drug intelligence / Profile preview

scd1 siRNA

Development stage
Preclinical
Lead developer
University of California, Los Angeles
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

scd1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Stearoyl-CoA Desaturase-1 (SCD-1), an enzyme responsible for the synthesis of monounsaturated fatty acids (MUFAs) such as oleate and palmitoleate. Research conducted at the David Geffen School of Medicine at UCLA suggests that SCD-1 upregulation in enterocytes, potentially driven by a 15-hydroxyeicosatetraenoic acid (15-HETE)-enriched diet, leads to increased circulating MUFAs. These lipids induce pulmonary artery endothelial cell (PAEC) dysfunction and promote smooth muscle cell (PASMC) proliferation, key mechanisms in the pathophysiology of pulmonary arterial hypertension (PAH). By silencing SCD-1, this siRNA aims to reduce MUFA production and mitigate the inflammatory and proliferative pathways contributing to vascular remodeling in pulmonary hypertension.

Other names
Scd1 siRNAScd-1 siRNAScd 1 siRNAStearoyl-CoA Desaturase-1 siRNA
02

Targets

SCD1 (Stearoyl-CoA desaturase 1)

Beyond the preview

Go deeper on scd1 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on scd1 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call